EuroMAbNet: European Monoclonal Antibodies NetworkEuroMAbNet. European Monoclonal Antibodies Network homepage



Sophia Karagiannis

Name of the laboratory

Professor of Translational Cancer Immunology and Immunotherapy
St. John's Institute of Dermatology
School of Basic & Medical Biosciences
King's College London, UK

Research Group Members

Members: St. John's Institute of Dermatology
Dr. Sophia Karagiannis
Dr Rebecca Adams (Clinical Research Fellow, PhD student & Dermatology Registrar)
Dr Heather Bax (Postdoctoral Research Fellow)
Ms Lucy Booth (MRC PhD student)
Mr Jitesh Chauhan (Research Assistant & PhD student)
Dr Alicia Chenoweth (BCN Postdoctoral Research Associate)
Dr Anthony Cheung (BCN Postdoctoral Research Associate)
Dr Silvia Crescioli (Postdoctoral Research Associate)
Benjamina Esapa (BBSRC PhD student)
Dr Melanie Grandits (Postdoctoral Research Associate)
Mr Roman Laddach (NHIR/BRC PhD student)
Ms Alexandra McCraw (MRC iCASE PhD student)
Mr Gabriel Osborn (MRC PhD student)
Dr Lais C G F Palhares (Postdoctoral Research Associate)
Mr Pablo Romero-Clavijo (Cancer Research UK PhD Student)
Dr Zena Willsmore (Cancer Research UK Clinical Fellow, PhD Student & Dermatology Registrar)

Summary of research

Our main research interests centre on designing antibody therapies for solid tumours such as melanoma, ovarian and breast carcinomas. Our antibody discovery pathway is informed through dissecting the B cell and antibody humoral immune responses to solid tumours as well as investigating the tumour-targeting mechanisms of IgE class antibodies and Th2 responses in cancer. Patient-derived antibodies and B cell responses are examined as potential biomarkers, with a view of developing stratified medicine approaches and patient-focused treatments. We are presently developing a pipeline of antibodies and our first-in-class agent has completed a Phase I clinical trial.

Research activities

Our laboratory’s activities are focused on the discovery and evaluation of monoclonal antibodies for clinically-challenging solid tumours such as melanoma, ovarian and breast carcinomas and on dissecting immune responses to cancer with particular focus on B cells and the antibodies they produce. Major research streams in our laboratory include: a) dissecting humoral responses and mechanisms of Th2-biased inflammation in tumours; b) interrogating patient humoral responses as potential biomarkers to aid stratification and with a view of developing patient-focused treatments; c) designing antibodies with potent effector functions and the interactions of antibodies with immune cells such as monocytes/macrophages, NK cells and basophils; d) elucidating antibody mechanisms of action in disease-relevant models.

Part of our research focuses on the nature and functions of B cells and antibodies in tumour immunity, particularly on tumour-resident and tumour-reactive B cell subsets and on antibody expression in tissues and the circulation. We have placed particular emphasis on antibody subclasses with immunosuppressive functions such as IgG4 which may suppress effector cell functions and block cytotoxic antibodies from eradicating cancer. We have demonstrated that antibodies produced in patients with melanoma can recognize and attack tumour cells. Despite producing antibodies recognising tumour cells, patients’ immune systems are mostly ineffective in restricting cancer growth. We have also shown that the tissue environment in tumours provides specific conditions, including production of cytokines like IL-10, which favour expression of IgG4 antibodies, resulting in antibody-mediated immune responses with reduced potency. We furthermore study patient-derived antibodies and B cell responses as potential biomarkers with a view of predicting clinical outcomes and developing patient-focused treatments.

Another key area of research relates to evaluating the impact of antibody class on the therapeutic efficacy of tumour antigen-specific antibodies. We are conducting studies directly comparing the efficacy and mechanisms of action of two different classes of antibodies, IgG and IgE. Our research suggests that compared to IgG, aspects of IgE biology are potentially suited to cancer therapy, including a higher binding affinity for Fc receptors, and the ability to activate different populations of potent effector cells normally present in tumour tissues to kill tumour cells. Our studies provide an insight into the diversity of mechanisms different classes of antibodies employ to activate immune effector cells such as monocytes/macrophages to target and kill tumours. Our most advanced agent, MOv18 IgE, recognising the α isoform of Folate Receptor, a tumour-associated antigen expressed almost exclusively in tissue cancers such as those of the ovary and subsets of breast cancers, has completed clinical testing. We continue to perform safety, efficacy, potency and mechanistic studies on this agent and we are developing a pipeline of IgE immunotherapeutic agents directed at cancer-associated antigens.

To interrogate antibody potency and mechanisms of action in recruiting, re-educating and activating human effector cell subsets against a range of target antigens, we are developing disease-relevant models featuring engraftment of different components of human immunity. Working with collaborating laboratories and biotechnology partners, we are developing novel antibody glyco-engineering approaches, antibody-drug conjugates, antibodies for further development in imaging studies and for cancer therapy, with the aim of expediting promising therapies and diagnostic tools from the laboratory bench to the patient bedside.

Grant support

Our research has been supported through project and programme grants by the National Institute for Health and Care Research (NIHR), Cancer Research UK and the CR UK New Agents Committee, Breast Cancer Now, the British Skin Foundation, Innovate UK, the Academy of Medical Sciences, the Biotechnology and Biological Sciences Research Council (BBSRC), and the Medical Research Council.

Publications (2019-present)

  • Chauhan J, Grandits M, Palhares LCGF, Mele S, Nakamura M, López-Abente J, Crescioli S, Laddach R, Romero-Clavijo P, Cheung A, Stavraka C, Chenoweth AM, Sow HS, Chiaruttini G, Gilbert AE, Dodev T, Koers A, Pellizzari G, Ilieva KM, Man F, Ali N, Hobbs C, Lombardi S, Lionarons D, Gould HJ, Beavil AJ, Geh JLC, MacKenzie Ross AD, Healy C, Calonje E, Downward J, Nestle FO, Tsoka S, Josephs DH, Blower PJ, Karagiannis P, Lacy KE, Spicer J, Karagiannis SN, Bax HJ. Anti-cancer pro-inflammatory effects of an IgE antibody targeting the melanoma-associated antigen chondroitin sulfate proteoglycan 4. Nat Commun. 2023;14(1):2192. doi: 10.1038/s41467-023-37811-3
  • Esapa B, Jiang J, Cheung A, Chenoweth A, Thurston DE, Karagiannis SN. Target Antigen Attributes and Their Contributions to Clinically Approved Antibody-Drug Conjugates (ADCs) in Haematopoietic and Solid Cancers. Cancers (Basel). 2023 Mar 19;15(6):1845.
  • Bax HJ, Chauhan J, Stavraka C, Santaolalla A, Osborn G, Khiabany A, Grandits M, López-Abente J, Palhares LCGF, Chan Wah Hak C, Robinson A, Pope A, Woodman N, Naceur-Lombardelli C, Malas S, Coumbe JEM, Nakamura M, Laddach R, Mele S, Crescioli S, Black AM, Lombardi S, Canevari S, Figini M, Sayasneh A, Tsoka S, FitzGerald K, Gillett C, Pinder S, Van Hemelrijck M, Kristeleit R, Ghosh S, Montes A, Spicer J, Karagiannis SN, Josephs DH. Folate receptor alpha in ovarian cancer tissue and patient serum is associated with disease burden and treatment outcomes. Br J Cancer, 2023 Jan;128(2):342-353.
  • Patel AJ, Willsmore ZN, Khan N, Richter A, Naidu B, Drayson MT, Papa S, Cope A, Karagiannis SN, Perucha E, Middleton GW. Regulatory B cell repertoire defects predispose lung cancer patients to immune-related toxicity following checkpoint blockade. Nat Commun. 2022 Jun 7;13(1):3148.
  • Crescioli S, White AL, Karagiannis SN. Special Issue "Antibody Engineering for Cancer Immunotherapy". Antibodies (Basel). 2022 Apr 15;11(2):29.
  • Monroy-Iglesias MJ, Crescioli S, Beckmann K, Le N, Karagiannis SN, Van Hemelrijck M, Santaolalla A. Antibodies as biomarkers for cancer risk: A systematic review. Clin Exp Immunol. 2022 Apr 4:uxac030. doi: 10.1093/cei/uxac030.
  • Amiri Souri E, Laddach R, Karagiannis SN, Papageorgiou LG, Tsoka S. Novel drug-target interactions via link prediction and network embedding. BMC Bioinformatics. 2022 Apr 4;23(1):121.
  • Adams R, Coumbe JEM, Coumbe BGT, Thomas J, Willsmore Z, Dimitrievska M, Yasuzawa-Parker M, Hoyle M, Ingar S, Geh JLC, MacKenzie Ross AD, Healy C, Papa S, Lacy KE, Karagiannis SN. BRAF inhibitors and their immunological effects in malignant melanoma. Expert Rev Clin Immunol. 2022 Apr;18(4):347-362.
  • Chauhan J, Stavraka C, Grandits M, Palhares LCGF, Josephs DH, Lacy KE, Spicer J, Bax HJ, Karagiannis SN. Clinical and Translational Significance of Basophils in Patients with Cancer. Cells. 2022 Jan 27;11(3):438.
  • Bergmann C, Poli A, Agache I, Bianchini R, Bax HJ, Castells M, Crescioli S, Dombrowicz D, Ferastraoaru D, Fiebiger E, Gould HJ, Hartmann K, Izquierdo E, Jordakieva G, Josephs DH, Jutel M, Levi-Schaffer F, de Las Vecillas L, Lotze MT, Osborn G, Pascal M, Redegeld F, Rosenstreich D, Roth-Walter F, Schmidt-Weber C, Shamji M, Steveling EH, Turner MC, Untersmayr E, Jensen-Jarolim E, Karagiannis SN. AllergoOncology: Danger signals in allergology and oncology: A European Academy of Allergy and Clinical Immunology (EAACI) Position Paper. Allergy. 2022 Feb 13. doi: 10.1111/all.15255.
  • Karagiannis P, Correa I, Chauhan J, Cheung A, Dominguez-Rodriguez D, Terranova-Barberio M, Harris RJ, Crescioli S, Spicer J, Bokemeyer C, Lacy KE, Karagiannis SN. Innate stimulation of B cells ex vivo enhances antibody secretion and identifies tumour-reactive antibodies from cancer patients. Clin Exp Immunol. 2022 Jan 28;207(1):84-94.
  • Egbuniwe IU, Harris RJ, Nakamura M, Nestle FO, Akbar AN, Karagiannis SN, Lacy KE. B Lymphocytes Accumulate and Proliferate in Human Skin at Sites of Cutaneous Antigen Challenge. J Invest Dermatol. 2022 Mar;142(3 Pt A):726-731.e4.
  • Harris RJ, Willsmore Z, Laddach R, Crescioli S, Chauhan J, Cheung A, Black A, Geh JLC, MacKenzie Ross AD, Healy C, Tsoka S, Spicer J, Kacy KE, Karagiannis SN*. Enriched circulating and tumor-resident TGFβ regulatory B cells in patients with melanoma promote FOXP3+ Tregs. Oncoimmunology, 2022 Jul 28;11(1):2104426.
  • McCraw AJ, Gardner RA, Davies AM, Spencer DIR, Grandits M, Wagner GK, McDonnell JM, Karagiannis SN, Chenoweth A, Crescioli S. Generation and Characterization of Native and Sialic Acid-Deficient IgE. Int J Mol Sci. 2022 Nov 3;23(21):13455
  • Handford J, Chen M, Rai R, Moss CL, Enting D, Peat N, Karagiannis SN, Van Hemelrijck M, Russell B. Is There a Role for Exercise When Treating Patients with Cancer with Immune Checkpoint Inhibitors? A Scoping Review. Cancers (Basel). 2022 Oct 14;14(20):5039.
  • Adams R, Osborn G, Mukhia B, Laddach R, Willsmore Z, Chenoweth A, Geh JLC, MacKenzie Ross AD, Healy C, Barber L, Tsoka S, Sanz-Moreno V, Lacy KE, Karagiannis SN. Influencing tumor-associated macrophages in malignant melanoma with monoclonal antibodies. Oncoimmunology. 2022 Oct 3;11(1):2127284.
  • Monroy-Iglesias MJ, Tremble K, Russell B, Moss C, Dolly S, Sita-Lumsden A, Cortellini A, Pinato DJ, Rigg A, Karagiannis SN, Van Hemelrijck M. Long-term effects of COVID-19 on cancer patients: the experience from Guy's Cancer Centre. Future Oncol. 2022 Oct;18(32):3585-3594.
  • Cheung A, Chenoweth AM, Quist J, Sow HS, Malaktou C, Ferro R, Hoffmann RM, Osborn G, Sachouli E, French E, Marlow R, Lacy KE, Papa S, Grigoriadis A, Karagiannis SN. CDK Inhibition Primes for Anti-PD-L1 Treatment in Triple-Negative Breast Cancer Models. Cancers (Basel). 2022 Jul 11;14(14):3361.
  • Karagiannis SN, Arnold JN. Immune cell-antibody interactions in health and disease. Clin Exp Immunol. 2022 Jul 22;209(1):1-3.
  • Osborn G, Stavraka C, Adams R, Sayasneh A, Ghosh S, Montes A, Lacy KE, Kristeleit R, Spicer J, Josephs DH, Arnold JN, Karagiannis SN. Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies. Clin Exp Immunol. 2021 Nov 22:uxab020. doi: 10.1093/cei/uxab020.
  • Li S, McCraw AJ, Gardner RA, Spencer DIR, Karagiannis SN, Wagner GK. Glycoengineering of Therapeutic Antibodies with Small Molecule Inhibitors. Antibodies (Basel). 2021 Nov 4;10(4):44.
  • Adams R, Moser B, Karagiannis SN, Lacy KE. Chemokine Pathways in Cutaneous Melanoma: Their Modulation by Cancer and Exploitation by the Clinician. Cancers (Basel). 2021 Nov 10;13(22):5625.
  • Chen M, Raj R, Fox L, Moss CL, George G, Karagiannis SN, Enting D, Joseph M, Peat N, Russell B, Van Hemelrijck M. Is there a role for physical activity when treating patients with cancer with immune checkpoint inhibitors? Protocol for a scoping review. BMJ Open. 2021 Oct 8;11(10):e046052.
  • Man F, Koers A, Karagiannis P, Josephs DH, Bax HJ, Gilbert AE, Dodev TS, Mele S, Chiaruttini G, Crescioli S, Chauhan J, Blower JE, Cooper MS, Spicer J, Karagiannis SN, Blower PJ. In vivo trafficking of a tumor-targeting IgE antibody: molecular imaging demonstrates rapid hepatobiliary clearance compared to IgG counterpart. Oncoimmunology. 2021 Sep 6;10(1):1966970.
  • McCraw AJ, Chauhan J, Bax HJ, Stavraka C, Osborn G, Grandits M, López-Abente J, Josephs DH, Spicer J, Wagner GK, Karagiannis SN, Chenoweth A, Crescioli S. Insights from IgE Immune Surveillance in Allergy and Cancer for Anti-Tumour IgE Treatments. Cancers (Basel). 2021 Sep 4;13(17):4460.
  • Santaolalla A, Sollie S, Rislan A, Josephs DH, Hammar N, Walldius G, Garmo H, Karagiannis SN, Van Hemelrijck M. Association between serum markers of the humoral immune system and inflammation in the Swedish AMORIS study. BMC Immunol. 2021 Sep 6;22(1):61.
  • Roulstone V, Mansfield D, Harris RJ, Twigger K, White C, de Bono J, Spicer J, Karagiannis SN, Vile R, Pandha H, Melcher A, Harrington K. Antiviral antibody responses to systemic administration of an oncolytic RNA virus: the impact of standard concomitant anticancer chemotherapies. J Immunother Cancer. 2021 Jul;9(7):e002673.
  • Harris RJ, Cheung A, Ng JCF, Laddach R, Chenoweth AM, Crescioli S, Fittall M, Dominguez-Rodriguez D, Roberts J, Levi D, Liu F, Alberts E, Quist J, Santaolalla A, Pinder SE, Gillett C, Hammar N, Irshad S, Van Hemelrijck M, Dunn-Walters DK, Fraternali F, Spicer JF, Lacy KE, Tsoka S, Grigoriadis A, Tutt ANJ, Karagiannis SN. Tumor-Infiltrating B Lymphocyte Profiling Identifies IgG-Biased, Clonally Expanded Prognostic Phenotypes in Triple-Negative Breast Cancer. Cancer Res. 2021 Aug 15;81(16):4290-4304.
  • Amiri Souri E, Chenoweth A, Cheung A, Karagiannis SN, Tsoka S. Cancer Grade Model: a multi-gene machine learning-based risk classification for improving prognosis in breast cancer. Br J Cancer. 2021 Aug;125(5):748-758.
  • Pellizzari G, Martinez O, Crescioli S, Page R, Di Meo A, Mele S, Chiaruttini G, Hoinka J, Batruch I, Prassas I, Grandits M, López-Abente J, Bugallo-Blanco E, Ward M, Bax HJ, French E, Cheung A, Lombardi S, Figini M, Lacy KE, Diamandis EP, Josephs DH, Spicer J, Papa S, Karagiannis SN. Immunotherapy using IgE or CAR T cells for cancers expressing the tumor antigen SLC3A2. J Immunother Cancer. 2021 Jun;9(6):e002140.
  • Runbeck E, Crescioli S, Karagiannis SN, Papa S. Utilizing Immunocytokines for Cancer Therapy. Antibodies (Basel). 2021 Mar 9;10(1):10.
  • Jordakieva G, Bianchini R, Reichhold D, Piehslinger J, Groschopf A, Jensen SA, Mearini E, Nocentini G, Crevenna R, Zlabinger GJ, Karagiannis SN, Klaus A, Jensen-Jarolim E. IgG4 induces tolerogenic M2-like macrophages and correlates with disease progression in colon cancer. Oncoimmunology. 2021 Feb 8;10(1):1880687.
  • Willsmore ZN, Harris RJ, Crescioli S, Hussein K, Kakkassery H, Thapa D, Cheung A, Chauhan J, Bax HJ, Chenoweth A, Laddach R, Osborn G, McCraw A, Hoffmann RM, Nakamura M, Geh JL, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Papa S, Barber L, Lacy KE, Karagiannis SN. B Cells in Patients With Melanoma: Implications for Treatment With Checkpoint Inhibitor Antibodies. Front Immunol. 2021 Jan 25;11:622442.
  • Abdul-Jawad S, Baù L, Alaguthurai T, Del Molino Del Barrio I, Laing AG, Hayday TS, Monin L, Muñoz-Ruiz M, McDonald L, Francos Quijorna I, McKenzie D, Davis R, Lorenc A, Chan JNE, Ryan S, Bugallo-Blanco E, Yorke R, Kamdar S, Fish M, Zlatareva I, Vantourout P, Jennings A, Gee S, Doores K, Bailey K, Hazell S, De Naurois J, Moss C, Russell B, Khan AA, Rowley M, Benjamin R, Enting D, Alrifai D, Wu Y, Zhou Y, Barber P, Ng T, Spicer J, Van Hemelrijck M, Kumar M, Vidler J, Lwin Y, Fields P, Karagiannis SN, Coolen ACC, Rigg A, Papa S, Hayday AC, Patten PEM, Irshad S. Acute Immune Signatures and Their Legacies in Severe Acute Respiratory Syndrome Coronavirus-2 Infected Cancer Patients. Cancer Cell. 2021 Feb 8;39(2):257-275.e6.
  • Willsmore ZN, Coumbe BGT, Crescioli S, Reci S, Gupta A, Harris RJ, Chenoweth A, Chauhan J, Bax HJ, McCraw A, Cheung A, Osborn G, Hoffmann RM, Nakamura M, Laddach R, Geh JLC, MacKenzie-Ross A, Healy C, Tsoka S, Spicer JF, Josephs DH, Papa S, Lacy KE, Karagiannis SN. Combined anti-PD-1 and anti-CTLA-4 checkpoint blockade: Treatment of melanoma and immune mechanisms of action. Eur J Immunol. 2021 Mar;51(3):544-556
  • Pranger CL, Fazekas-Singer J, Köhler VK, Pali-Schöll I, Fiocchi A, Karagiannis SN, Zenarruzabeitia O, Borrego F, Jensen-Jarolim E. PIPE-cloned human IgE and IgG4 antibodies: New tools for investigating cow's milk allergy and tolerance. Allergy. 2021 May;76(5):1553-1556.
  • Nakamura M, Souri EA, Osborn G, Laddach R, Chauhan J, Stavraka C, Lombardi S, Black A, Khiabany A, Khair DO, Figini M, Winship A, Ghosh S, Montes A, Spicer JF, Bax HJ, Josephs DH, Lacy KE, Tsoka S, Karagiannis SN. IgE Activates Monocytes from Cancer Patients to Acquire a Pro-Inflammatory Phenotype. Cancers (Basel). 2020 Nov 15;12(11):3376.
  • Rodriguez-Hernandez I, Maiques O, Kohlhammer L, Cantelli G, Perdrix-Rosell A, Monger J, Fanshawe B, Bridgeman VL, Karagiannis SN, Penin RM, Marcolval J, Marti RM, Matias-Guiu X, Fruhwirth GO, Orgaz JL, Malanchi I, Sanz-Moreno V. WNT11-FZD7-DAAM1 signalling supports tumour initiating abilities and melanoma amoeboid invasion. Nat Commun. 2020 Oct 20;11(1):5315.
  • Chauhan J, McCraw AJ, Nakamura M, Osborn G, Sow HS, Cox VF, Stavraka C, Josephs DH, Spicer JF, Karagiannis SN, Bax HJ. IgE Antibodies against Cancer: Efficacy and Safety. Antibodies (Basel). 2020 Oct 16;9(4):55.
  • Köhler VK, Crescioli S, Fazekas-Singer J, Bax HJ, Hofer G, Pranger CL, Hufnagl K, Bianchini R, Flicker S, Keller W, Karagiannis SN, Jensen-Jarolim E. Filling the Antibody Pipeline in Allergy: PIPE Cloning of IgE, IgG1 and IgG4 against the Major Birch Pollen Allergen Bet v 1. Int J Mol Sci. 2020 Aug 8;21(16):5693.
  • Bianchini R, Karagiannis SN, Jordakieva G, Jensen-Jarolim E. The Role of IgG4 in the Fine Tuning of Tolerance in IgE-Mediated Allergy and Cancer. Int J Mol Sci. 2020 Jul 16;21(14):5017.
  • Ferastraoaru D, Bax HJ, Bergmann C, Capron M, Castells M, Dombrowicz D, Fiebiger E, Gould HJ, Hartmann K, Jappe U, Jordakieva G, Josephs DH, Levi-Schaffer F, Mahler V, Poli A, Rosenstreich D, Roth-Walter F, Shamji M, Steveling-Klein EH, Turner MC, Untersmayr E, Karagiannis SN, Jensen-Jarolim E. AllergoOncology: ultra-low IgE, a potential novel biomarker in cancer-a Position Paper of the European Academy of Allergy and Clinical Immunology (EAACI). Clin Transl Allergy. 2020 Jul 17;10:32.
  • Bax HJ, Chauhan J, Stavraka C, Khiabany A, Nakamura M, Pellizzari G, Ilieva KM, Lombardi S, Gould HJ, Corrigan CJ, Till SJ, Katugampola S, Jones PS, Barton C, Winship A, Ghosh S, Montes A, Josephs DH, Spicer JF, Karagiannis SN. Basophils from Cancer Patients Respond to Immune Stimuli and Predict Clinical Outcome. Cells. 2020 Jul 7;9(7):1631.
  • Hoffmann RM, Mele S, Cheung A, Larcombe-Young D, Bucaite G, Sachouli E, Zlatareva I, Morad HOJ, Marlow R, McDonnell JM, Figini M, Lacy KE, Tutt AJN, Spicer JF, Thurston DE, Karagiannis SN, Crescioli S. Rapid conjugation of antibodies to toxins to select candidates for the development of anticancer Antibody-Drug Conjugates (ADCs). Sci Rep. 2020 Jun 1;10(1):8869.
  • Pellizzari G, Bax HJ, Josephs DH, Gotovina J, Jensen-Jarolim E, Spicer JF, Karagiannis SN. Harnessing Therapeutic IgE Antibodies to Re-educate Macrophages against Cancer. Trends Mol Med. 2020 Jun;26(6):615-626.
  • Hoffmann RM, Crescioli S, Mele S, Sachouli E, Cheung A, Chui CK, Andriollo P, Jackson PJM, Lacy KE, Spicer JF, Thurston DE, Karagiannis SN. A Novel Antibody-Drug Conjugate (ADC) Delivering a DNA Mono-Alkylating Payload to Chondroitin Sulfate Proteoglycan (CSPG4)-Expressing Melanoma. Cancers (Basel). 2020 Apr 22;12(4):1029.
  • Gotovina J, Bianchini R, Fazekas-Singer J, Herrmann I, Pellizzari G, Haidl ID, Hufnagl K, Karagiannis SN, Marshall JS, Jensen-Jarolim E. Epinephrine drives human M2a allergic macrophages to a regulatory phenotype reducing mast cell degranulation in vitro. Allergy. 2020 Nov;75(11):2939-2942.
  • Sollie S, Santaolalla A, Michaud DS, Sarker D, Karagiannis SN, Josephs DH, Hammar N, Walldius G, Garmo H, Holmberg L, Jungner I, Van Hemelrijck M. Serum Immunoglobulin G Is Associated With Decreased Risk of Pancreatic Cancer in the Swedish AMORIS Study. Front Oncol. 2020 Feb 28;10:263.
  • Martin TC, Ilieva KM, Visconti A, Beaumont M, Kiddle SJ, Dobson RJB, Mangino M, Lim EM, Pezer M, Steves CJ, Bell JT, Wilson SG, Lauc G, Roederer M, Walsh JP, Spector TD, Karagiannis SN. Dysregulated Antibody, Natural Killer Cell and Immune Mediator Profiles in Autoimmune Thyroid Diseases. Cells. 2020 Mar 9;9(3):665.
  • Bax HJ, Khiabany A, Stavraka C, Pellizzari G, Chan Wah Hak C, Robinson A, Ilieva KM, Woodman N, Naceur-Lombardelli C, Gillett C, Pinder S, Gould HJ, Corrigan CJ, Till SJ, Katugampola S, Barton C, Winship A, Ghosh S, Montes A, Josephs DH, Spicer JF, Karagiannis SN. Basophil activation test in cancer patient blood evaluating potential hypersensitivity to an anti-tumor IgE therapeutic candidate. Allergy. 2020 Aug;75(8):2069-2073.
  • Urwyler P, Earnshaw I, Bermudez M, Perucha E, Wu W, Ryan S, Mcdonald L, Karagiannis SN, Taams LS, Powell N, Cope A, Papa S. Mechanisms of checkpoint inhibition-induced adverse events. Clin Exp Immunol. 2020 May;200(2):141-154.
  • Orgaz JL, Crosas-Molist E, Sadok A, Perdrix-Rosell A, Maiques O, Rodriguez-Hernandez I, Monger J, Mele S, Georgouli M, Bridgeman V, Karagiannis P, Lee R, Pandya P, Boehme L, Wallberg F, Tape C, Karagiannis SN, Malanchi I, Sanz-Moreno V. Myosin II Reactivation and Cytoskeletal Remodeling as a Hallmark and a Vulnerability in Melanoma Therapy Resistance. Cancer Cell. 2020 Jan 13;37(1):85-103.e9.
  • Peppas I, George G, Sollie S, Josephs DH, Hammar N, Walldius G, Karagiannis SN, Van Hemelrijck M. Association of Serum Immunoglobulin Levels with Solid Cancer: A Systematic Review and Meta-analysis. Cancer Epidemiol Biomarkers Prev. 2020 Mar;29(3):527-538.
  • Williams IP, Crescioli S, Sow HS, Bax HJ, Hobbs C, Ilieva KM, French E, Pellizzari G, Cox V, Josephs DH, Spicer JF, Karagiannis SN, Mele S. In vivo safety profile of a CSPG4-directed IgE antibody in an immunocompetent rat model. MAbs. 2020 Jan-Dec;12(1):1685349.
  • Kessler A, Sollie S, Karagiannis SN, Walldius G, Hammar N, Van Hemelrijck M. Serum IgG Is Associated With Risk of Melanoma in the Swedish AMORIS Study. Front Oncol. 2019 Oct 29;9:1095.
  • Montero-Morales L, Maresch D, Crescioli S, Castilho A, Ilieva KM, Mele S, Karagiannis SN, Altmann F, Steinkellner H. In Planta Glycan Engineering and Functional Activities of IgE Antibodies. Front Bioeng Biotechnol. 2019 Sep 25;7:242.
  • Sutton BJ, Davies AM, Bax HJ, Karagiannis SN. IgE Antibodies: From Structure to Function and Clinical Translation. Antibodies (Basel). 2019 Feb 22;8(1):19.
  • Sollie S, Michaud DS, Sarker D, Karagiannis SN, Josephs DH, Hammar N, Santaolalla A, Walldius G, Garmo H, Holmberg L, Jungner I, Van Hemelrijck M. Chronic inflammation markers are associated with risk of pancreatic cancer in the Swedish AMORIS cohort study. BMC Cancer. 2019 Aug 29;19(1):858.
  • Peppas I, Sollie S, Josephs DH, Hammar N, Walldius G, Karagiannis SN, Van Hemelrijck M. Serum immunoglobulin levels and the risk of bladder cancer in the AMORIS Cohort. Cancer Epidemiol. 2019 Oct;62:101584.
  • Singer J, Achatz-Straussberger G, Bentley-Lukschal A, Fazekas-Singer J, Achatz G, Karagiannis SN, Jensen-Jarolim E. AllergoOncology: High innate IgE levels are decisive for the survival of cancer-bearing mice. World Allergy Organ J. 2019 Jul 29;12(7):100044.
  • Nakamura M, Bax HJ, Scotto D, Souri EA, Sollie S, Harris RJ, Hammar N, Walldius G, Winship A, Ghosh S, Montes A, Spicer JF, Van Hemelrijck M, Josephs DH, Lacy KE, Tsoka S, Karagiannis SN. Immune mediator expression signatures are associated with improved outcome in ovarian carcinoma. Oncoimmunology. 2019 Mar 28;8(6):e1593811.
  • Ilieva KM, Fazekas-Singer J, Bax HJ, Crescioli S, Montero-Morales L, Mele S, Sow HS, Stavraka C, Josephs DH, Spicer JF, Steinkellner H, Jensen-Jarolim E, Tutt ANJ, Karagiannis SN. AllergoOncology: Expression platform development and functional profiling of an anti-HER2 IgE antibody. Allergy. 2019 Oct;74(10):1985-1989.
  • Pellizzari G, Hoskin C, Crescioli S, Mele S, Gotovina J, Chiaruttini G, Bianchini R, Ilieva K, Bax HJ, Papa S, Lacy KE, Jensen-Jarolim E, Tsoka S, Josephs DH, Spicer JF, Karagiannis SN. IgE re-programs alternatively-activated human macrophages towards pro-inflammatory anti-tumoural states. EBioMedicine. 2019 May;43:67-81.
  • Khair DO, Bax HJ, Mele S, Crescioli S, Pellizzari G, Khiabany A, Nakamura M, Harris RJ, French E, Hoffmann RM, Williams IP, Cheung A, Thair B, Beales CT, Touizer E, Signell AW, Tasnova NL, Spicer JF, Josephs DH, Geh JL, MacKenzie Ross A, Healy C, Papa S, Lacy KE, Karagiannis SN. Combining Immune Checkpoint Inhibitors: Established and Emerging Targets and Strategies to Improve Outcomes in Melanoma. Front Immunol. 2019 Mar 19;10:453.
  • Georgouli M, Herraiz C, Crosas-Molist E, Fanshawe B, Maiques O, Perdrix A, Pandya P, Rodriguez-Hernandez I, Ilieva KM, Cantelli G, Karagiannis P, Mele S, Lam H, Josephs DH, Matias-Guiu X, Marti RM, Nestle FO, Orgaz JL, Malanchi I, Fruhwirth GO, Karagiannis SN, Sanz-Moreno V. Regional Activation of Myosin II in Cancer Cells Drives Tumor Progression via a Secretory Cross-Talk with the Immune Microenvironment. Cell. 2019 Feb 7;176(4):757-774.e23.
  • Untersmayr E, Bax HJ, Bergmann C, Bianchini R, Cozen W, Gould HJ, Hartmann K, Josephs DH, Levi-Schaffer F, Penichet ML, O'Mahony L, Poli A, Redegeld FA, Roth-Walter F, Turner MC, Vangelista L, Karagiannis SN, Jensen-Jarolim E. AllergoOncology: Microbiota in allergy and cancer-A European Academy for Allergy and Clinical Immunology position paper. Allergy. 2019 Jun;74(6):1037-1051.